Original Research Article I Volume 1 I Issue 3 I 2015
Cardiovascular Disease Risk Factors Among HIV Patients
P. Sanjeev Reddy
American Journal of Science and Medical Research; 1(3); 92-100
DOI:http://dx.doi.org/10.17812/ajsmr2015132
Abstract:
Metabolic disturbances and fat redistribution have been characterized in HIV-infected patients receiving combination antiretroviral therapy according to drug exposure and patterns of fat redistribution. In contrast, we investigated metabolic abnormalities in a well-characterized cohort of HIV-infected patients with clinical lipodystrophy in comparison with an established population of healthy control subjects with known cardiovascular disease (CVD) risk parameters. In order to establish the extent of lipid abnormalities, glucose intolerance, and increased CVD risk in HIV-infected men and women experiencing lipodystrophy, we evaluated metabolic and clinical parameters in comparison with healthy control subjects.
Keywords:
Cardiovascular Disease, HIV, Hyperinsulinemia and Metabolic disturbances
References:
[1]. Anderson RL, Hamman RF, Savage PJ, et al. Exploration of simple insulin sensitivity measures derived from frequently sampled intravenous glucose tolerance (FSIGT) tests. Am J Epidemiol 1995; 142:724–32.
[2]. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63–70.
[3]. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitor therapy. AIDS 1998; 12:F51–8.
[4]. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1–protease-inhibitor-associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. Lancet 1998; 351:1881–3.
[5]. Carr A, Samaras K, Thorisdottir A, Kaufman GR, Chisolm DJ, Cooper DA. Diagnosis, prediction, and natural course ofHIV-1 protease-inhibitor associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093–9.
[6]. Feskens EJ, Kromhout D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J Clin Epidemiol 1992; 45:1327–34.
[7]. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral treatment. AIDS 1999; 13:465–71.
[8]. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045–52.
[9]. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Use of metformin for the treatment of the HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284:472–7.
[10]. Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in HIV-infected men: relationship to body composition, gonadal function and protease-inhibitor use. J Clin Endocrinol Metab 2000; 85:35–41...
Article Dates:
Received: 28 June 2015; Accepted: 3 August 2015; Published: 12 August 2015
How To Cite:
P. Sanjeev Reddy (2015). Cardiovascular Disease Risk Factors Among HIV Patients. The American Journal of Science and Medical Research, 1(3):92-100. doi:10.17812/ajsmr2015132 Received 28 June, 2015; 3 August, 2015 Published online 12 August, 2015
